Abstract
Objective: We studied physicians’ opinions and experiences concerning clinical concerns, perceived severity, occurrence, and management of baclofen withdrawal due to abrupt discontinuation. Methods: A nationwide 26-question electronic survey was distributed via e-mail to physicians (N = 952) representing varying specialties who manage spasticity with baclofen. A total of 110 physicians provided responses to the survey (response rate = 11.6%). Results were evaluated using descriptive statistics. Results: Withdrawal from both oral and intrathecal (IT) baclofen was recognized as a significant concern and was observed by most respondents. However, approximately 75% and 35% of respondents or their clinic sites lack established management protocols for managing anticipated interruption of oral or IT baclofen, respectively. Conclusions: These findings highlight the need for further research on and the development of guidelines for the prevention and treatment of baclofen withdrawal. The results of this survey, along with a systematic literature review and multidisciplinary stakeholder input, may be helpful in establishing guidelines for the treatment and prevention of baclofen withdrawal.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 106-109 |
| Number of pages | 4 |
| Journal | Pediatric Neurology |
| Volume | 122 |
| DOIs | |
| State | Published - Sep 1 2021 |
Bibliographical note
Publisher Copyright:© 2021 Elsevier Inc.
Keywords
- Baclofen
- Baclofen administration & dosage
- Baclofen adverse effects
- Muscle relaxants
- Muscle spasticity
- Muscle spasticity/drug therapy
- Substance withdrawal syndrome/therapy
- Survey